Ashish Adukia
Global CFO
Notable Quotes
The guidance will have to be revised because if we don't have lanreotide in one quarter, the numbers will be lower.
Our outlook for projected EBITDA margin is in the range of about 23.5%-24.5%.
The EBITDA margin stood at impressive 28% for the quarter, up by 184 basis points YOY and 138 basis points QOQ.
North America reached all-time high quarterly revenue of $250 million.
Our EBITDA for the year is trending in the range of 24.5%-25.5% and ROIC is well over 30%.
The whole idea is to actually grow that value this year.
Our EBITDA for the year is trending in the range of, so we are increasing our guidance on EBITDA from 23%, what we had given earlier, to 23%-24%, with bias towards the higher end.
We expect the full year EBITDA to be trending towards 23% for the year.